We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Cardiac Trials for Arena Obesity Drug Can Be Done Postmarket, Panel Says
Cardiac Trials for Arena Obesity Drug Can Be Done Postmarket, Panel Says
June 6, 2012
Despite supporting a requirement that sponsors evaluate cardiac risks of weight-loss drugs both pre- and postmarket just months earlier, an FDA advisory panel voted 18–4 with one abstention in May in favor of approving Arena’s weight-loss drug lorcaserin, saying postmarket studies could suffice in this case.